Handelsbanken Fonder AB Takes Position in Disc Medicine, Inc. $IRON

Handelsbanken Fonder AB purchased a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 12,700 shares of the company’s stock, valued at approximately $929,000.

Other large investors have also recently bought and sold shares of the company. NEXTBio Capital Management LP acquired a new stake in Disc Medicine during the 4th quarter worth about $3,397,000. DNB Asset Management AS lifted its position in shares of Disc Medicine by 1,425.8% in the fourth quarter. DNB Asset Management AS now owns 84,255 shares of the company’s stock worth $6,691,000 after purchasing an additional 78,733 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in shares of Disc Medicine by 10,968.6% in the fourth quarter. Pictet Asset Management Holding SA now owns 394,374 shares of the company’s stock worth $31,317,000 after purchasing an additional 390,811 shares in the last quarter. Eagle Health Investments LP acquired a new stake in shares of Disc Medicine during the fourth quarter worth approximately $2,152,000. Finally, Vanguard Group Inc. grew its position in Disc Medicine by 22.1% during the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock valued at $140,371,000 after purchasing an additional 319,621 shares in the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Trading Up 0.1%

NASDAQ:IRON opened at $80.32 on Thursday. The company has a market capitalization of $307.63 million, a P/E ratio of -12.21 and a beta of 1.00. The stock’s 50 day moving average price is $75.39 and its 200 day moving average price is $69.91. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. On average, research analysts forecast that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IRON has been the topic of several research reports. Morgan Stanley reiterated an “overweight” rating and issued a $90.00 price objective on shares of Disc Medicine in a research note on Monday. Wall Street Zen upgraded shares of Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. HC Wainwright increased their price objective on Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Wedbush reissued an “outperform” rating and set a $88.00 price objective on shares of Disc Medicine in a research report on Wednesday, June 10th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Disc Medicine has an average rating of “Moderate Buy” and a consensus price target of $106.50.

Insider Activity

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 18,612 shares of the stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28. Following the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $3,758,677.56. This represents a 25.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rahul Khara sold 7,500 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $70.22, for a total value of $526,650.00. Following the transaction, the insider owned 52,173 shares in the company, valued at approximately $3,663,588.06. This trade represents a 12.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 144,516 shares of company stock worth $10,675,929. 3.76% of the stock is owned by corporate insiders.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.